LYMPHOMA, B-CELL
Clinical trials for LYMPHOMA, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, B-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for seniors with aggressive lymphoma: targeted drug combo tested
Disease control OngoingThis study tests whether adding polatuzumab vedotin to a standard chemotherapy regimen (R-miniCHP) can help people aged 75 and older with a type of lymphoma called DLBCL. The goal is to see if the combination improves how long patients live without their cancer getting worse. Abo…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
New hope for Hard-to-Treat lymphoma: safer combo therapy in trials
Disease control OngoingThis early-phase study tests a new drug added to standard chemotherapy for people with aggressive B-cell lymphoma that has come back or not responded to treatment. The main goal is to find the highest dose that is safe and does not cause severe side effects. About 40 participants…
Matched conditions: LYMPHOMA, B-CELL
Phase: EARLY_PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 17, 2026 05:33 UTC
-
New cell therapy shows promise for tough blood cancers
Disease control OngoingThis early-phase study tests a new treatment called FT819 for people with certain blood cancers (B-cell lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia) that have not responded to standard therapies. The treatment uses specially engineered immune cells to…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for tough lymphomas: experimental drug targets resistant cancers
Disease control OngoingThis study tests an experimental drug called valemetostat tosylate in 141 people with B-cell lymphoma that has returned or not responded to prior therapy. The drug is a pill taken by mouth that aims to shrink tumors. Researchers are checking how well it works and how safe it is a…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1, PHASE2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Lifeline for patients: extended ibrutinib access trial launches
Disease control OngoingThis study offers ongoing access to the drug ibrutinib for people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and are still seeing benefits. Participants continue their treatment while researchers collect long-term safety informa…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE4 • Sponsor: Pharmacyclics Switzerland GmbH • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Engineered immune cells with 'Kill Switch' offer new hope for lymphoma patients
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The T-cells are engineered to recognize and attack cancer cells, but also include a safety switch that can be activated to reduce severe…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New CAR T-Cell therapy shows promise for tough blood cancers
Disease control OngoingThis early-stage trial tests a new treatment for B-cell cancers (like leukemia and lymphoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Smarter dosing may cut chemo side effects in lymphoma transplant
Symptom relief OngoingThis study tests a new way to calculate the dose of the chemotherapy drug melphalan for lymphoma patients getting a stem cell transplant. Instead of a standard dose based on height and weight, researchers use a model that considers how previous patients processed the drug. The go…
Matched conditions: LYMPHOMA, B-CELL
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated May 17, 2026 05:34 UTC